Adjuvant Endocrine Therapy

Mechanism

Related News

Oncology Innovations: ENVISION Trial Results, AI Integration, and Real-Time Symptom Monitoring

Mar 29, 2026

The phase 3 ENVISION trial shows 80% complete response rate for novel bladder cancer chemoablative therapy. AI integration accelerates precision oncology through biomarker identification and targeted treatments. OncoPRO real-time symptom monitoring system enhances patient safety and clinical trial data capture.

Cryoablation System Shows 83.9% Recurrence-Free Rate in Kidney Cancer Trial

Mar 26, 2026

The ProSense Cryoablation System achieved an 83.9% recurrence-free rate in kidney cancer patients after 4 years in the ICESECRET trial. The system treats small renal masses up to 5 cm and is approved in multiple global markets. Detailed results will be presented at the European Conference on Interventional Oncology in April 2026.